As of 2025-07-02, the Relative Valuation of Y-mAbs Therapeutics, Inc (YMAB) is (13.14) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.41 USD, the upside of Y-mAbs Therapeutics, Inc based on Relative Valuation is -398.0%.
The range of the Relative Valuation is (8.29) - (16.40) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.8x - 26.3x | 19.6x |
| Forward P/E multiples | 13.3x - 31.9x | 22.6x |
| Fair Price | (8.29) - (16.40) | (13.14) |
| Upside | -288.0% - -471.8% | -398.0% |
| Date | P/E |
| 2025-07-01 | -7.07 |
| 2025-06-30 | -7.23 |
| 2025-06-27 | -7.54 |
| 2025-06-26 | -7.70 |
| 2025-06-25 | -7.87 |
| 2025-06-24 | -8.23 |
| 2025-06-23 | -7.57 |
| 2025-06-20 | -7.07 |
| 2025-06-18 | -7.43 |
| 2025-06-17 | -7.70 |
| 2025-06-16 | -7.92 |
| 2025-06-13 | -7.55 |
| 2025-06-12 | -7.43 |
| 2025-06-11 | -7.91 |
| 2025-06-10 | -8.20 |
| 2025-06-09 | -8.15 |
| 2025-06-06 | -8.45 |
| 2025-06-05 | -8.18 |
| 2025-06-04 | -7.95 |
| 2025-06-03 | -7.81 |
| 2025-06-02 | -7.60 |
| 2025-05-30 | -7.38 |
| 2025-05-29 | -7.62 |
| 2025-05-28 | -7.41 |
| 2025-05-27 | -7.07 |
| 2025-05-23 | -6.93 |
| 2025-05-22 | -6.62 |
| 2025-05-21 | -6.58 |
| 2025-05-20 | -6.78 |
| 2025-05-19 | -6.69 |
| 2025-05-16 | -6.58 |
| 2025-05-15 | -6.19 |
| 2025-05-14 | -5.84 |
| 2025-05-13 | -6.67 |
| 2025-05-12 | -6.53 |
| 2025-05-09 | -6.24 |
| 2025-05-08 | -6.48 |
| 2025-05-07 | -6.22 |
| 2025-05-06 | -6.19 |
| 2025-05-05 | -6.82 |
| 2025-05-02 | -7.07 |
| 2025-05-01 | -6.59 |
| 2025-04-30 | -6.82 |
| 2025-04-29 | -6.74 |
| 2025-04-28 | -6.78 |
| 2025-04-25 | -6.58 |
| 2025-04-24 | -6.62 |
| 2025-04-23 | -6.61 |
| 2025-04-22 | -6.83 |
| 2025-04-21 | -7.73 |